openPR Logo
Press release

Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals

10-10-2025 03:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Lambert Eaton Myasthenic Syndrome Market Positioned

The Key Lambert Eaton Myasthenic Syndrome Companies in the market include - Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others.

DelveInsight's "Lambert Eaton Myasthenic Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Lambert Eaton Myasthenic Syndrome, historical and forecasted epidemiology as well as the Lambert Eaton Myasthenic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Lambert Eaton Myasthenic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lambert Eaton Myasthenic Syndrome Market Forecast [https://www.delveinsight.com/sample-request/lambert-eaton-myasthenic-syndrome-lems-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Lambert Eaton Myasthenic Syndrome Market Report:

*
The Lambert Eaton Myasthenic Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In October 2025, Catalyst Pharmaceuticals, Inc. announced that its research findings will be showcased at several upcoming scientific conferences, highlighting its commitment to developing treatments for patients with rare diseases. The presentations will feature studies on glucocorticoid therapy in Duchenne Muscular Dystrophy at the Child Neurology Society Annual Meeting and the AANEM Annual Meeting, as well as research on treatments for Lambert-Eaton Myasthenic Syndrome. Known for its rapid growth and achievements in the biopharmaceutical sector, Catalyst remains dedicated to improving patient care and access to innovative therapies that have a meaningful impact on patients' lives.

*
In August 2025, Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company dedicated to in-licensing, developing, and commercializing novel therapies for patients with rare and hard-to-treat conditions, announced that the National Comprehensive Cancer Network Registered (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines Registered ) for Small Cell Lung Cancer (SCLC) have been updated. The new guidelines now include additions related to Lambert-Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE Registered ), and testing for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.

*
In 2023, the United States had the highest prevalence of cases among the 7MM.

*
In 2023, Germany reported the highest number of prevalent cases of Lambert-Eaton Myasthenic Syndrome among the EU4 and the UK, followed by France and the UK. Conversely, Spain had the fewest cases.

*
Lambert-Eaton Myasthenic Syndrome is classified into two types based on its etiology: paraneoplastic and idiopathic.

*
Key Lambert Eaton Myasthenic Syndrome Companies: Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others

*
Key Lambert Eaton Myasthenic Syndrome Therapies: Continuous 3,4-DAP, FIRDAPSE (amifampridine), and others

*
The Lambert Eaton Myasthenic Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lambert Eaton Myasthenic Syndrome pipeline products will significantly revolutionize the Lambert Eaton Myasthenic Syndrome market dynamics.

Lambert Eaton Myasthenic Syndrome Overview

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder characterized by weakness and fatigue in the muscles, particularly those involved in voluntary movement. It occurs when the immune system mistakenly attacks the body's own cells, specifically targeting the voltage-gated calcium channels at the neuromuscular junction. This impairs the release of acetylcholine, a neurotransmitter crucial for muscle contraction.

LEMS is often associated with certain types of cancer, particularly small cell lung cancer, and can present with symptoms such as muscle weakness, difficulty walking, and drooping eyelids. Unlike myasthenia gravis, another neuromuscular disorder, LEMS typically features improved muscle strength with repeated use of the muscle.

Get a Free sample for the Lambert Eaton Myasthenic Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/lambert-eaton-myasthenic-syndrome-lems-market [https://www.delveinsight.com/report-store/lambert-eaton-myasthenic-syndrome-lems-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lambert Eaton Myasthenic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Lambert Eaton Myasthenic Syndrome Epidemiology Segmentation:

The Lambert Eaton Myasthenic Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Lambert Eaton Myasthenic Syndrome

*
Prevalent Cases of Lambert Eaton Myasthenic Syndrome by severity

*
Gender-specific Prevalence of Lambert Eaton Myasthenic Syndrome

*
Diagnosed Cases of Episodic and Chronic Lambert Eaton Myasthenic Syndrome

Download the report to understand which factors are driving Lambert Eaton Myasthenic Syndrome epidemiology trends @ Lambert Eaton Myasthenic Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/lambert-eaton-myasthenic-syndrome-lems-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lambert Eaton Myasthenic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lambert Eaton Myasthenic Syndrome market or expected to get launched during the study period. The analysis covers Lambert Eaton Myasthenic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lambert Eaton Myasthenic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Lambert Eaton Myasthenic Syndrome Therapies and Key Companies

*
Continuous 3,4-DAP: Jacobus Pharmaceutical

*
FIRDAPSE (amifampridine): Catalyst Pharmaceuticals

Discover more about therapies set to grab major Lambert Eaton Myasthenic Syndrome market share @ Lambert Eaton Myasthenic Syndrome Treatment Landscape [https://www.delveinsight.com/sample-request/lambert-eaton-myasthenic-syndrome-lems-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lambert Eaton Myasthenic Syndrome Market Drivers

*
Increasing Awareness

*
Advancements in Treatment

*
Rising Diagnosis Rates

*
Supportive Regulatory Environment

*
Growing Research and Development

Lambert Eaton Myasthenic Syndrome Market Barriers

*
Limited Patient Population

*
High Treatment Costs

*
Complicated Diagnosis

*
Lack of Awareness

*
Market Access Challenges

Scope of the Lambert Eaton Myasthenic Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Lambert Eaton Myasthenic Syndrome Companies: Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others

*
Key Lambert Eaton Myasthenic Syndrome Therapies: Continuous 3,4-DAP, FIRDAPSE (amifampridine), and others

*
Lambert Eaton Myasthenic Syndrome Therapeutic Assessment: Lambert Eaton Myasthenic Syndrome current marketed and Lambert Eaton Myasthenic Syndrome emerging therapies

*
Lambert Eaton Myasthenic Syndrome Market Dynamics: Lambert Eaton Myasthenic Syndrome market drivers and Lambert Eaton Myasthenic Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Lambert Eaton Myasthenic Syndrome Unmet Needs, KOL's views, Analyst's views, Lambert Eaton Myasthenic Syndrome Market Access and Reimbursement

To know more about Lambert Eaton Myasthenic Syndrome companies working in the treatment market, visit @ Lambert Eaton Myasthenic Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/lambert-eaton-myasthenic-syndrome-lems-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Lambert Eaton Myasthenic Syndrome Market Report Introduction

2. Executive Summary for Lambert Eaton Myasthenic Syndrome

3. SWOT analysis of Lambert Eaton Myasthenic Syndrome

4. Lambert Eaton Myasthenic Syndrome Patient Share (%) Overview at a Glance

5. Lambert Eaton Myasthenic Syndrome Market Overview at a Glance

6. Lambert Eaton Myasthenic Syndrome Disease Background and Overview

7. Lambert Eaton Myasthenic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Lambert Eaton Myasthenic Syndrome

9. Lambert Eaton Myasthenic Syndrome Current Treatment and Medical Practices

10. Lambert Eaton Myasthenic Syndrome Unmet Needs

11. Lambert Eaton Myasthenic Syndrome Emerging Therapies

12. Lambert Eaton Myasthenic Syndrome Market Outlook

13. Country-Wise Lambert Eaton Myasthenic Syndrome Market Analysis (2020-2034)

14. Lambert Eaton Myasthenic Syndrome Market Access and Reimbursement of Therapies

15. Lambert Eaton Myasthenic Syndrome Market Drivers

16. Lambert Eaton Myasthenic Syndrome Market Barriers

17. Lambert Eaton Myasthenic Syndrome Appendix

18. Lambert Eaton Myasthenic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lambert-eaton-myasthenic-syndrome-market-positioned-for-accelerated-development-through-2034-delveinsight-finds-jacobus-pharmaceutical-catalyst-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals here

News-ID: 4218277 • Views:

More Releases from ABNewswire

New YA Adventure
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure. Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is
Hudkins Publishing Music Launches Three Volumes of Background Music for Commercial Use Relaxation, Focus, And Atmosphere
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business. KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus. Each collection features 30 professionally produced instrumental tracks, available in both WAV
Book Now the Emerging Gospel Artist
Book Now the Emerging Gospel Artist "Jacqueline L. Jenkins" debuts new single "A …
BIOGRAPHY Jacqueline L. Jenkins is an emerging gospel artist celebrated for her heartfelt lyrics and soulful vocals that blend traditional gospel spirit with contemporary rhythms. She first gained recognition with her debut single, "Thank You," which resonated deeply with listeners through its message of gratitude and faith. In 2024, Jacqueline released the Thank You - EP, featuring standout tracks such as "Going Home," a poignant tribute to her late mother, and
Why More People Are Choosing Mobile Hair and Beauty Services Through DashStylists
Why More People Are Choosing Mobile Hair and Beauty Services Through DashStylist …
People are seeking a means of making their lives easier in the hectic world we all live in. Mobile beauty and hair services are one of the trends that are on the rise. These services help save time and efforts as the salon experience has been delivered to the home of the customer. Customers do not have to drive to a salon, wait until their turn comes and then drive

All 5 Releases


More Releases for Lambert

Lambert-Eaton Myasthenic Syndrome (LEMS) Market to Reach USD 280 Million by 2034
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs, fatigue, and autonomic dysfunction. It occurs when antibodies target voltage-gated calcium channels (VGCCs) at the neuromuscular junction, impairing acetylcholine release. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71907 Approximately 50-60% of LEMS cases are paraneoplastic, most often associated with small-cell lung cancer (SCLC). The remainder are autoimmune and non-cancer related. LEMS remains underdiagnosed
How the Lambert-Eaton Myasthenic Syndrome Market Is Growing in 2025 | What's New …
The expansion of the market is attributed to an increase in awareness, incidence, and availability of new and advanced therapies. Lambert-Eaton Myasthenic Syndrome (LEMS), also a rare autoimmune disorder, disrupts communication between nerves and muscles, causing weakness and fatigue. It is mostly associated with small cell lung cancer but can also appear in individuals with no underlying malignancies. LEMS is another rare disease; however, in recent times, there has been a
Global Lambert-Eaton Myasthenic Syndrome Treatment Market - Industry Trends and …
Global Lambert-Eaton Myasthenic Syndrome Treatment Market - Industry Trends and Forecast to 2028 The lambert-eaton myasthenic syndrome treatment market is expected to witness market growth at a rate of 6.56% in the forecast period of 2021 to 2028. Data Bridge Market Research report on lambert-eaton myasthenic syndrome treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the
Global Pentostatin Market 2019 Scenario of Top Sellers: • Hospira (Pfizer),• …
The "Pentostatin market" study formulated by Up Market Research, presents a detailed analysis of the influential trends prevailing in this business sphere. This research report also offers definitive information concerning the commercialization of this vertical, market size, and revenue estimation of this industry. The study explicitly illustrates the competitive standing of key players over the projected timeline while incorporating their individual portfolios & geographical expansion. The Global Pentostatin market 2019
Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market Forecast over 2017 …
Some of the key players operating the global laser diffraction equipment market are Malvern Instruments Ltd, HORIBA, Ltd, Fritsch GmbH, Shimadzu Corporation, Beckman Coulter, Inc., Micrometrics Instrument Corporation, Angstrom Advanced Inc., Sympatc GmbH among others worldwide. To maintain a significant position in the global laser diffraction equipment market some of the major players are operating strategies like investment in R and D sector to broaden their product portfolios. The players are
Bond Refinancing Saves St. Louis Lambert International Airport $35 Million
(ST. LOUIS) Comptroller Darlene Green announced that the City of St. Louis saved more than $35 million by refinancing $242 million of outstanding St. Louis Lambert International Airport bonds. “With favorable market conditions, the City of St. Louis was able to deliver a $35 million present value savings for St. Louis Lambert International Airport that will reduce future debt payments and increase financial flexibility for airport operations and planning,” said